Kowa Teva And Nippon Kayaku To Collaborate On Biosimilars
This article was originally published in PharmAsia News
Executive Summary
Japanese generic drug joint venture Teva Kowa and Nippon Kayaku obtained the rights to develop and market follow-on biologics of granulocyte colony-stimulating factor from Teva Pharmaceutical Industries